Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone XR Extension in Alzheimer's Disease
NCT00490568Phase 3Terminated
- Sponsor
- GSK
- Start
- Aug 2007
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 29
01
Overview
Phase 3, open-label, single-arm trial of rosiglitazone in Alzheimer's disease (AD), sponsored by GSK. Primary endpoint: Number of Participants With Any Adverse Events (AEs) and Severity of AEs at 76 weeks. Started Aug 2007; status: terminated.
02
Drugs
rosiglitazone
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00490568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00490568.